Federal Register / Vol. 82, No. 213 / Monday, November 6, 2017 / Notices 51427 

In the Federal Register of January 6, 

2000 (65 FR 1000), we published a final 

rule (the ‘structure/function final rule) 

on statements made for dietary 

supplements concerning the effect of the 

product on the structure or function of 

the body. In that final rule, we estimated 

that there were 29,000 dietary 

supplement products marketed in the 

United States (65 FR 1000 at 1045). 

Assuming that the flow of new products 

is 10 percent per year, then 2,900 new 

dietary supplement products will come 

on the market each year. The structure/ 

function final rule estimated that about 

69 percent of dietary supplements have 

a claim on their labels, most probably a 

structure/function claim (65 FR 1000 at 

1046). Therefore, we assume that 

supplement manufacturers will need 

time to assemble the evidence to 

substantiate each of the 2,001 claims 

(2,900 × 69 percent) made each year. If 

we assume that the 2,001 claims are 

equally likely to be preexisting widely 

established claims, novel claims, or 

preexisting claims that are not widely 

established, then we can expect 667 of 

each of these types of claims to be 

substantiated per year. Table 1 of this 

document shows that the annual burden 

hours associated with assembling 

evidence for claims is 189,428 (the sum 

of 667 × 44 hours, 667 × 120 hours, and 

667 × 120 hours). 

Dated: October 31, 2017. 

Anna K. Abram, 

Deputy Commissioner for Policy, Planning, 

Legislation, and Analysis. 

[FR Doc. 2017–24123 Filed 11–3–17; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Mental Health; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel; 

NIMH HIV/AIDS Review (P30, T32). 

Date: November 28, 2017. 

Time: 12:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: David W. Miller, Ph.D., 

Scientific Review Officer, Division of 

Extramural Activities, National Institute of 

Mental Health, NIH, Neuroscience Center, 

6001 Executive Blvd, Room 6140, MSC 9608, 

Bethesda, MD 20892–9608, 301–443–9734, 

millerda@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program No. 93.242, Mental Health Research 

Grants; National Institutes of Health, HHS) 

Dated: October 31, 2017. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–24034 Filed 11–3–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Respiratory Sciences. 

Date: November 15–16, 2017. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Sara Ahlgren, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, RM 4136, 

Bethesda, MD 20892, 301–435–0904, 

sara.ahlgren@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Blood 

Disorders. 

Date: November 15, 2017. 

Time: 10:00 a.m. to 11:00 a.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Luis Espinoza, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4140, 

MSC 7814, Bethesda, MD 20892, 301–435– 

0952, espinozala@mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Neurological, Neuropsychological 

Disorders and Aging. 

Date: November 17, 2017. 

Time: 10:00 a.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Samuel C. Edwards, Ph.D., 

Chief, Brain Disorders and Clinical 

Neuroscience, Center for Scientific Review, 

National Institutes of Health, 6701 Rockledge 

Drive, Room 5210, MSC 7846, Bethesda, MD 

20892, (301) 435–1246, edwardss@

csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: AIDS and AIDS Related Research. 

Date: November 28, 2017. 

Time: 12:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Mark P. Rubert, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5218, 

MSC 7852, Bethesda, MD 20892, 301–435– 

1775, rubertm@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Dermatology, Rheumatology and 

Inflammation. 

Date: November 29, 2017. 

Time: 10:30 a.m. to 5:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892. 

Contact Person: Rajiv Kumar, Ph.D., Chief, 

MOSS IRG, Center for Scientific Review, 

National Institutes of Health, 6701 Rockledge 

Drive, Room 4216, MSC 7802, Bethesda, MD 

20892, 301–435–1212, kumarra@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: HIV/AIDS Innovative Research 

Applications. 

Date: November 30, 2017. 

Time: 1:00 p.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting) 

Contact Person: Jose H. Guerrier, Ph.D., 

Scientific Review Officer, Center for 


Pmangrum on DSK3GDR082PROD with NOTICES
51428 Federal Register / Vol. 82, No. 213 / Monday, November 6, 2017 / Notices 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5218, 

MSC 7852, Bethesda, MD 20892, 301–435– 

1137, guerriej@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: October 31, 2017. 

Sylvia L. Neal, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–24032 Filed 11–3–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; NIAID Clinical Trial 

Implementation Grant (R01). 

Date: November 27, 2017. 

Time: 3:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health 5601 

Fishers Lane, Rockville, MD 20892 

(Telephone Conference Call). 

Contact Person: Chelsea D. Boyd, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, DEA/NIAID/NIH/DHHS, 5601 

Fishers Lane, MSC–9823 Rockville, MD 

20852–9834, 240–669–2081, chelsea.boyd@

nih.gov. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; NIH Support for 

Conferences and Scientific Meetings (Parent 

R13). 

Date: November 30, 2017. 

Time: 2:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health 5601 

Fishers Lane, Rockville, MD 20892 

(Telephone Conference Call). 

Contact Person: Vasundhara Varthakavi, 

DVM, Ph.D., Scientific Review Officer 

Scientific Review Program, Division of 

Extramural Activities, Room 3E70, National 

Institutes of Health, NIAID, 5601 Fishers 

Lane, MSC 9823, Bethesda, MD 20892–9823, 

(240) 669–5020, varthakaviv@niaid.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: October 31, 2017. 

Natasha M. Copeland, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–24033 Filed 11–3–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF THE INTERIOR 

Fish and Wildlife Service 

[FWS–R8–ES–2017–N133; 

FXES11130800000–178–FF08EVEN00] 

Receipt of Application for Incidental 

Take Permit; Draft Low-Effect Habitat 

Conservation Plan for the California 

Tiger Salamander; Phillips 66 Line 300 

Project, Santa Barbara County, 

California 

AGENCY: Fish and Wildlife Service, 

Interior. 

ACTION: Notice of availability; request 

for comments. 

SUMMARY: We, the U.S. Fish and 

Wildlife Service (Service), have received 

an application from Phillips 66 

Pipeline, LLC for an incidental take 

permit under the Endangered Species 

Act of 1973, as amended. The permit 

would authorize take of the federally 

endangered California tiger salamander 

(Santa Barbara distinct population 

segment), incidental to otherwise lawful 

activities associated with the Phillips 66 

Line 300 Project draft low-effect habitat 

conservation plan. We invite public 

comment. 

DATES: Written comments should be 

received on or before December 6, 2017. 

ADDRESSES:

To obtain documents: You may 

download a copy of the draft habitat 

conservation plan and draft low-effect 

screening form and environmental 

action statement at http://www.fws.gov/ 

ventura/, or you may request copies of 

the documents by sending U.S. mail to 

our Ventura office, or by phone (see FOR

FURTHER INFORMATION CONTACT). 

To submit written comments: Please 

send us your written comments using 

one of the following methods: 

• U.S. mail: Send your comments to: 

Stephen P. Henry, Field Supervisor, 

Ventura Fish and Wildlife Office, U.S. 

Fish and Wildlife Service, 2493 Portola 

Road, Suite B, Ventura, CA 93003. 

• Facsimile: Fax your comments to 

805–644–3958. 

FOR FURTHER INFORMATION CONTACT: 

Rachel Henry, Fish and Wildlife 

Biologist, 805–677–3312 (phone), or at 

the Ventura address in ADDRESSES. 

SUPPLEMENTARY INFORMATION: We have 

received an application from Phillips 66 

Pipeline, LLC (applicant) for an 

incidental take permit under the 

Endangered Species Act of 1973, as 

amended (16 U.S.C. 1531 et seq.; ESA). 

The applicant has agreed to follow all of 

the conditions in the draft habitat 

conservation plan for the project. The 

permit would authorize take of the 

Santa Barbara distinct population 

segment of the federally endangered 

California tiger salamander (Ambystoma 

californiense) incidental to otherwise 

lawful activities associated with the 

draft Phillips 66 Line 300 Project 

Habitat Conservation Plan (HCP). We 

invite public comment on the 

application, the draft HCP, draft loweffect screening form, and 

environmental action statement. 

Background 

The Santa Barbara distinct population 

segment (DPS) of the California tiger 

salamander was listed by the Service as 

endangered on September 21, 2000 (65 

FR 57242). Section 9 of the ESA and its 

implementing regulations prohibit the 

‘‘take’’ of fish or wildlife species listed 

as endangered or threatened. ‘‘Take’’ is 

defined under the ESA to include the 

following activities: ‘‘[T]o harass, harm, 

pursue, hunt, shoot, wound, kill, trap, 

capture, or collect, or to attempt to 

engage in any such conduct’’ (16 U.S.C. 

1532); however, under section 

10(a)(1)(B) of the ESA, we may issue 

permits to authorize incidental take of 

listed species. ‘‘Incidental take’’ is 

defined by the ESA as take that is 

incidental to, and not the purpose of, 

carrying out of an otherwise lawful 

activity. Regulations governing 

incidental take permits for threatened 

and endangered species are in the Code 

of Federal Regulations (CFR) at 50 CFR 

17.32 and 17.22, respectively. Under the 

ESA, protections for federally listed 

plants differ from the protections 

afforded to federally listed animals. 

Issuance of an incidental take permit 

also must not jeopardize the existence of 

federally listed fish, wildlife, or plant 

species. The permittee would receive 

assurances under our ‘‘No Surprises’’ 

regulations (50 CFR 17.22(b)(5) and 


Pmangrum on DSK3GDR082PROD with NOTICES